scholarly journals In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012–2018

2020 ◽  
Author(s):  
Shio-Shin Jean ◽  
Wen-Sen Lee ◽  
Wen-Chien Ko ◽  
Po-Ren Hsueh
Keyword(s):  
Klebsiella Pneumoniae ◽  
Gram Positive ◽  
In Vitro Susceptibility ◽  
Haemophilus Species ◽  
Gram Positive Cocci

scholarly journals Susceptibility of Bacterial Endophthalmitis Isolates to Vancomycin, Ceftazidime, and Amikacin

2021 ◽  
Author(s):  
Kuan-Jen Chen ◽  
Ming-Hui Sun ◽  
Chiun-Ho Hou ◽  
Hung-Chi Chen ◽  
Yen-Po Chen ◽  
...  
Keyword(s):  
Klebsiella Pneumoniae ◽  
Vision Loss ◽  
Multidrug Resistant ◽  
Coagulase Negative Staphylococci ◽  
Gram Positive ◽  
In Vitro Susceptibility ◽  
Gram Negative ◽  
Tertiary Referral Center ◽  
Bacterial Endophthalmitis

Abstract Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial endophthalmitis isolates in specimens at a tertiary referral center from January 1996 to April 2019 in Taiwan. Overall, 450 (49.9%) isolates were gram positive, 447 (49.6%) were gram negative, and 4 (0.4%) were gram variable. In gram-positive isolates, coagulase-negative staphylococci were the most commonly cultured bacteria (158, 35.1%), followed by streptococci (100, 22.2%), enterococci (75, 16.7%), and Staphylococcus aureus (70, 15.6%). In gram-negative isolates, they were Klebsiella pneumoniae (166, 37.1%) and Pseudomonas aeruginosa (131, 29.3%). All gram-positive organisms were susceptible to vancomycin, with the exception of one Enterococcus faecium isolate (1/450, 0.2%). Of the gram-negative isolates, 96.9% and 93.7% were susceptible to ceftazidime and amikacin, respectively. Nine isolates (9/447, 2.0%) were multidrug-resistant gram-negative bacteria, comprising Klebsiella pneumoniae (4/164, 2.4%), Acinetobacter baumannii (2/3, 67%), and Stenotrophomonas maltophilia (3/18, 17%). In conclusion, in vitro susceptibility testing revealed that vancomycin remains the suitable antibiotic treatment for gram-positive endophthalmitis. Ceftazidime and amikacin provide approximately the same degree of gram-negative coverage. Multidrug-resistant bacterial endophthalmitis was uncommon.

scholarly journals In vitro susceptibility of gram-positive cocci to paldimycin.

1987 ◽  
Vol 31 (1) ◽  
pp. 104-107 ◽  
Author(s):  
D J Pohlod ◽  
L D Saravolatz ◽  
M M Somerville
Keyword(s):  
Gram Positive ◽  
In Vitro Susceptibility ◽  
Gram Positive Cocci

Use of Fosfomycin Etest® to Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other Than Escherichia coli , Non-Fermenting Gram-Negative Bacilli, and Gram-positive Cocci

2021 ◽  
Author(s):  
James A. Karlowsky ◽  
Melanie R. Baxter ◽  
Alyssa R. Golden ◽  
Heather J. Adam ◽  
Andrew Walkty ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Clinical Isolates ◽  
High Rate ◽  
Major Error ◽  
Gram Positive ◽  
In Vitro Susceptibility ◽  
Gram Negative ◽  
Agar Dilution ◽  
Gram Positive Cocci

Clinical isolates of Enterobacterales other than Escherichia coli (EOTEC), non-fermenting Gram-negative bacilli, and Gram-positive cocci were tested for susceptibility to fosfomycin using Etest ® and reference agar dilution. Applying EUCAST (v. 11.0, 2021) intravenous fosfomycin breakpoints, Etest ® MICs for EOTEC showed essential agreement (EA), categorical agreement (CA), major error (ME), and very major error (VME) rates of 70.4%, 88.4%, 4.1%, and 32.1%, respectively. No species of EOTEC tested with acceptable rates for all of EA (≥90%), CA (≥90%), ME (≤3%), and VME (≤3%). Etest ® MICs for Enterococcus faecalis , interpreted using CLSI oral/urine criteria (M100, 2021), showed EA, CA, minor error, ME, and VME rates of 98.5%, 81.2%, 18.8%, 0%, and 0%. Against Staphylococcus aureus , EA, CA, and ME rates were 84.1%, 98.7%, and 1.3% (EUCAST intravenous criteria). S. aureus isolates with fosfomycin MICs >32 μg/ml (resistant) were not identified by agar dilution. We conclude performing fosfomycin Etest ® on isolates of S. aureus will reliably identify fosfomycin-susceptible isolates with low, acceptable rates of MEs and VMEs. Testing of urinary isolates of E. faecalis by Etest ® is associated with an unacceptably high rate of minor errors (18.8%) but low, acceptable rates of MEs and VMEs when results are interpreted using CLSI criteria. Isolates of EOTEC tested by Etest ® with resulting MICs interpreted by EUCAST criteria were associated with an unacceptably high VME rate (32.1%). In vitro testing of clinical isolates beyond E. coli , E. faecalis , and S. aureus to determine susceptibility to fosfomycin is problematic with current methods and breakpoints.

In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci

2013 ◽  
Vol 41 (3) ◽  
pp. 213-217 ◽  
Author(s):  
Russell Hope ◽  
Aiysha Chaudhry ◽  
Rachael Adkin ◽  
David M. Livermore
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Positive Cocci

Comparative in vitro activity of ceftobiprole against Gram-positive cocci

2010 ◽  
Vol 36 (2) ◽  
pp. 111-113 ◽  
Author(s):  
Carmen Betriu ◽  
Esther Culebras ◽  
María Gómez ◽  
Fátima López-Fabal ◽  
Iciar Rodríguez-Avial ◽  
...  
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Positive Cocci

Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment

2021 ◽  
Author(s):  
Federica Romanelli ◽  
Stefania Stolfa ◽  
Anna Morea ◽  
Luigi Ronga ◽  
Raffaele Del Prete ◽  
...  
Keyword(s):  
Klebsiella Pneumoniae ◽  
Turning Point ◽  
Treatment Strategies ◽  
Blood Cultures ◽  
Clinical Isolates ◽  
In Vitro Susceptibility ◽  
Klebsiella Pneumoniae Carbapenemase ◽  
Lactamase Inhibitor

Aim: Infections by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae represent a major challenge because of limited treatment strategies. New β-lactam/β-lactamase inhibitor associations may help to deal with this challenge. The aim of this study is to evaluate the in vitro susceptibility of KPC-producing K. pneumoniae for meropenem/vaborbactam in comparison with ceftazidime/avibactam against. Materials and methods: Twenty-eight strains isolated from blood cultures were evaluated. Testing for susceptibility to meropenem/vaborbactam and ceftazidime/avibactam was performed by E-test gradient strip. Results: All the clinical isolates were susceptible to meropenem/vaborbactam, while one strain was resistant to ceftazidime/avibactam with a MIC of 32 μg/ml. The median MIC of ceftazidime/avibactam evaluated after standardization was higher compared with that of meropenem/vaborbactam. Conclusion: Meropenem/vaborbactam could be an important turning point in the treatment of KPC-producing K. pneumoniae infections, especially considering the emergence of ceftazidime/avibactam resistance.

Sign in / Sign up

Export Citation Format

Share Document